Duodenal Stenting Still Leads Palliative Care for Malignant Gastric Outlet Obstruction
Malignant gastric outlet obstruction remains one of the most disabling complications of advanced gastric, pancreatic, and duodenal cancer. Nausea, recurrent vomiting, pain, dehydration, and protein-calorie malnutrition can escalate quickly, turning oral intake into a daily struggle and often forcing urgent decisions about decompression, endoscopic intervention, and nutrition support. This practice review set out to bring order to that bedside complexity by assembling evidence-based recommendations for non-surgical palliation across pharmacological, decompressive, endoscopic, and nutritional strategies.
The clinical message is direct: treatment choice should be anchored in prognosis, symptom burden, and patient preference, not in a one-size-fits-all pathway.
The review used a scoping methodology to assess the strength of evidence behind guideline-endorsed interventions. Relevant national and international guidance was identified through web searches and the TRIP database, with reference lists hand-searched for primary studies. A supplementary structured MEDLINE search in 2024 captured newer research. That approach matters because practice in this area has often outpaced the evidence base, leaving clinicians to balance symptom relief against procedural burden in patients with limited reserve.
Symptom Control Depends on More Than a Single Drug Class
Pharmacological treatment remains central in day-to-day palliation, but the evidence base is thin. Opioids, antiemetics, and antisecretory agents are widely used to reduce pain, vomiting, and upper gastrointestinal secretions, yet there is limited direct evidence of efficacy specifically in malignant gastric outlet obstruction. In practical terms, these drugs are often doing supportive work rather than resolving the obstruction itself. They may soften the symptom spiral enough to permit oral comfort measures, facilitate transfer for endoscopy, or reduce distress when more invasive palliation is not possible.
The mechanism is clinically intuitive. Opioids can blunt pain and improve tolerance of manipulation, antiemetics can dampen central and peripheral emetic drive, and antisecretory agents can reduce volume burden proximal to the obstruction. Still, the review makes clear that evidence for the best combination, sequence, and duration remains unsettled. In a syndrome defined by mechanical blockage, symptom drugs help most when they are aligned with a definitive decompressive plan.
Decompression Has a Role, but Prolonged Nasogastric Use Should Be Avoided
When endoscopy is not feasible or obstruction is acute, decompression with a nasogastric tube or venting gastrostomy is advised. The purpose is straightforward: relieve pressure, reduce vomiting, and make the patient more comfortable while the next step is considered. Acute obstruction can produce a rapid cascade of aspiration risk, electrolyte disturbance, and severe distress, so decompression can be an immediate bedside stabilizer.
Prolonged nasogastric tube use, however, should be avoided. The review supports short-term decompression rather than open-ended reliance on a tube that can worsen discomfort, impair communication, and interfere with daily care. A venting gastrostomy offers a more durable decompressive option when the clinical situation calls for longer-term palliation and endoscopy is not possible for definitive luminal treatment.
Endoscopic Palliation Favors Stenting, with Gastroenterostomy Gaining Ground
For endoscopic palliation, duodenal stenting remains first-line. The appeal is immediate luminal restoration with a minimally invasive approach that can restore gastric emptying and reduce the burden of persistent vomiting. In advanced cancer, where time and physiologic reserve are often limited, a procedure that offers rapid symptom relief can be the difference between maintaining some oral intake and complete dependence on decompression.
Endoscopic gastroenterostomy is emerging as an important alternative. Evidence supporting its effectiveness is growing, and the review argues that it should be considered alongside established approaches. The biological logic is persuasive: by creating a bypass around the obstruction, gastroenterostomy can restore downstream transit without relying on a blocked duodenum. For selected patients, especially where expected survival and technical expertise support the choice, the procedure may offer a durable way to preserve intake and reduce recurrent obstruction symptoms.
Selection between stenting and gastroenterostomy should not be framed as a purely technical competition. The right choice depends on prognosis, anatomy, local expertise, and patient priorities. A patient hoping for the fastest possible relief may be best served by stenting, while another with a longer expected course may benefit from a bypass strategy that better resists re-obstruction.
Nutrition Assessment Should Start Early, Even When the Best Route Is Unclear
Early nutritional assessment is recommended in all patients with malignant gastric outlet obstruction. Obstruction robs patients of intake at precisely the point when cancer-related catabolism, inflammation, and treatment-related fatigue are already eroding nutritional status. Weight loss and sarcopenia can quickly narrow functional reserve, and even short interruptions in oral intake may worsen weakness, reduce treatment tolerance, and intensify caregiver burden.
The review stops short of defining the optimal modality or duration of nutritional supplementation. Enteral and parenteral options may each be relevant depending on whether gastric passage can be restored, whether decompression is ongoing, and whether the patient’s prognosis justifies a more intensive approach. The unresolved question is not whether nutrition matters; it does. The unresolved question is how to deliver it in a way that respects comfort, feasibility, and realistic goals of care.
Multidisciplinary Planning Shapes the Right Intervention
The strongest recommendation in the review is not a device or a drug. It is a process. Multidisciplinary care, with early assessment of prognosis and patient preference, should guide intervention choice from the start.
That approach is especially important in advanced gastrointestinal malignancy, where the same patient may be eligible for symptom medication, endoscopic palliation, decompression, and nutrition support at different points in the illness. The decision is rarely binary. A patient may begin with decompression, move to stenting, and then need nutritional reassessment as disease progresses. The care plan has to be responsive enough to follow that trajectory without delaying relief.
A second concrete need emerges from the evidence gap: better studies of drug combinations and standardized quality-of-life measures. Without common endpoints, it remains difficult to compare interventions that may all relieve vomiting but differ in comfort, durability, and impact on daily function. The review calls for integrated care pathways built around patient-centered outcomes rather than procedural success alone.
For now, the practical hierarchy is clear enough for bedside use. Duodenal stenting remains the leading endoscopic option, endoscopic gastroenterostomy deserves consideration as evidence matures, decompression has a defined role when endoscopy is not possible, and pharmacological therapy should be used as adjunctive symptom control rather than assumed definitive treatment. The missing piece is a common, validated way to measure what matters most to patients living with malignant gastric outlet obstruction: relief, oral intake, and comfort in the time they have left.